Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 205

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Lysyl Oxidase–Like 2 as a New Poor Prognosis Marker of Squamous Cell Carcinomas

Peinado, Héctor, Moreno-Bueno, Gema, Hardisson, David, Pérez-Gómez, Eduardo, Santos, Vanesa, Mendiola, Marta, de Diego, Juan Ignacio, Nistal, Manuel, Quintanilla, Miguel, Portillo, Francisco, Cano, Amparo·2008·Cancer Research

Abstract

Lysyl oxidase–like 2 (Loxl2) interacts with and stabilizes Snai1 transcription factor, promoting epithelial-mesenchymal transition. Either Loxl2 or Snai1 knock-down blocks tumor growth and induces differentiation, but the specific role of each factor in tumor progression is still unknown. Comparison of the gene expression profiles of the squamous cell carcinoma cell line HaCa4 after knocking-down Loxl2 or Snai1 revealed that a subset of epidermal differentiation genes was specifically up-regulated in Loxl2-silenced cells. In agreement, although both Loxl2- and Snai1-knockdown cells showed reduced in vivo invasion, only Loxl2-silenced cells exhibited a skin-like epidermal differentiation program. In addition, we show that expression of Loxl2 and Snai1 correlates with malignant progression in a two-stage mouse skin carcinogenesis model. Furthermore, we found that increased expression of both LOXL2 and SNAI1 correlates with local recurrence in a cohort of 256 human laryngeal squamous cell carcinomas. We describe for the first time that high levels of LOXL2 are associated with decreased overall and disease-free survival in laryngeal squamous cell carcinomas, lung squamous cell carcinoma, and lymph node–negative (N0) breast adenocarcinomas. Altogether, our results show that LOXL2 can be used as a new poor prognosis indicator in human squamous cell carcinomas promoting malignant transformation by both SNAI1-dependent and SNAI1-independent pathways. [Cancer Res 2008;68(12):4541–50]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-07-6345

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 5 references

Cited by

See all 205

Metadata

Authors
Peinado, H., Moreno-Bueno, G., Hardisson, D., Pérez-Gómez, E., Santos, V., Mendiola, M., de Diego, J. I., Nistal, M., Quintanilla, M., Portillo, F., & Cano, A.
Venue
Cancer Research
Published
2008-06-15
Volume
68
Issue
12
Pages
4541-4550
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2135652726
Cited by
205
References
5
FWCI
6.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lysyl Oxidase–Like 2 as a New Poor Prognosis Marker of Squamous Cell Carcinomas. https://app.cochat.ai/papers/10.1158/0008-5472.can-07-6345
The paper
Peinado, H., Moreno-Bueno, G., Hardisson, D., Pérez-Gómez, E., Santos, V., Mendiola, M., de Diego, J. I., Nistal, M., Quintanilla, M., Portillo, F., & Cano, A. (2008). Lysyl Oxidase–Like 2 as a New Poor Prognosis Marker of Squamous Cell Carcinomas. Cancer Research. https://doi.org/10.1158/0008-5472.can-07-6345

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.